BIOMARKER FOR THE PREDICTION OF RESPONSIVENESS TO AN ANTI-TUMOUR NECROSIS FACTOR ALPHA (TNF) TREATMENT

摘要

The invention refers to a method for diagnosing an individual who is to besubjected to or is being subjected to ananti-tumour necrosis factor alpha (TNFa or TNF) treatment to asses theresponsiveness to an anti-TNF treatment which comprisesthe detection of immunoglobulin(s) against one or more biomarker proteins in abodily fluid or an excrement of said patient, andsorting the individual into one of two categories based on detection of saidimmunoglobulin(s), wherein individuals are classifiedas NON-responder or responder. The invention refers to diagnostic kitscomprising said one or more biomarker proteins and theuse of these kits for assessing the responsiveness to an anti-TNF treatment ofan individual who is to be subjected to or is beingsubjected to an anti-TNFa treatment.